Buy Full Version
"Behcets Disease Market"

Let us help you !

Invalid Email.

Please Select Country.

Invalid contact no.

Special Symbols Not Allowed.

Invalid Security Code.

Thank You For Your Interest.

We've Successfully Got Your Message,

Our Executive will get back to you Shortly.

Behcets Disease Market by Treatment Type [Corticosteroids, Immunosuppressive Agents and Immunomodulators] and by Symptoms [Eyes, Bowels, Skin and Mucosa, Lungs, Brain, Bones, Blood Vessels and Heart] - Global Opportunity Analysis and Industry Forecast, 2019-2026

Pharmaceuticals	LI_184403	Pages: NA	Jan 2020 \| 2197 Views
Author(s) : NA	Tables: NA	Charts: NA	Formats*:

Behcets disease is an inflammatory and non-contagious disorder which can affect multiple parts of the body. The cause of this disease is still unknown but it is believed to be partly genetic. This condition often progresses with the passage of time. Diagnosis for Behcets disease is based on at least three incidents of mouth sores in a year together with at least two genital sores, eye inflammation, skin sores, a positive skin prick test.

Major factors that drive the market growth are the rise in incidences of Behcets disease globally. For instance, according to the American Behcets Disease Association (ABDA) there are approximately 16,000-20,000 cases of Behcet's disease in the U.S. and this disease is most prevalent in Turkey in which approximately 400 cases for every 100,000 individuals have been observed. However, lack of awareness among individuals and healthcare professionals will act as a restraint for the growth of this market. Moreover, technological advancements in healthcare industry and increasing R&D expenditure by the government will aid in creating lucrative opportunities for key market players.

The global Behcets disease market is segmented based on treatment type, symptoms and region. Based on treatment type this market is segmented into corticosteroids, immunosuppressive agents and immunomodulators. Corticosteroids are further sub segmented into methylprednisolone, prednisone and dexamethasone. Immunosuppressive agents are sub segmented into azathioprine, cyclophosphamide and chlorambucil. Immunomodulators are further sub segmented into colchicine, dapsone and sulfasalazine. Based on symptoms this market is segmented into eyes, bowels, skin and mucosa, lungs, brain, bones, blood vessels and heart. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players, such as Creabilis Ltd, Cell Medica Limited, Actelion Ltd, Abbott Laboratories, Novartis AG, Les Laboratoires, Servier SAS, AbbVie Inc., Celgene Corporation and F. Hoffmann-La Roche Ltd. are also provided in this report.

Key Benefits

This report provides an extensive analysis of the current and emerging trends and dynamics in the global Behcet's disease market.
In-depth analysis is done by constructing market estimations for the key market segments between 2016 and 2023 to identify the prevailing market opportunities.
This study evaluates the competitive landscape and value chain to understand the competitive environment across the geographies.
Comprehensive analysis of factors that drive and restrict the market growth is provided.
Comprehensive analysis of all regions is provided to determine the prevailing opportunities in these geographies.

Behcets Disease Market Key Segments:

By Treatment Type

Corticosteroids
- Methylprednisolone
- Prednisone
- Dexamethasone
Immunosuppressive Agents
- Azathioprine
- Cyclophosphamide
- Chlorambucil
Immunomodulators
- Colchicine
- Dapsone
- Sulfasalazine

By Symptoms

Eyes
Bowels
Skin and Mucosa
Lungs
Brain
Bones
Blood vessels
Heart

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- U.K.
- France
- Germany
- Spain
- Rest of Europe
Asia-Pacific
- China
- India
- Australia
- Japan
- Rest of Asia-Pacific
LAMEA
- Brazil
- Turkey
- Saudi Arabia
- South Africa
- Rest of LAME

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS/TOP PLAYER POSITIONING, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

CHAPTER 4 BEHCET’S DISEASE MARKET, BY TREATMENT TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. CORTICOSTEROIDS

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.2.4. Methylprednisolone

4.2.4.1. Market size and forecast

4.2.5. Prednisone

4.2.5.1. Market size and forecast

4.2.6. Dexamethasone

4.2.6.1. Market size and forecast

4.3. IMMUNOSUPPRESSIVE AGENTS

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. Azathioprine

4.3.4.1. Market size and forecast

4.3.5. Cyclophosphamide

4.3.5.1. Market size and forecast

4.3.6. Chlorambucil

4.3.6.1. Market size and forecast

4.4. IMMUNOMODULATORS

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.4.4. Colchicine

4.4.4.1. Market size and forecast

4.4.5. Dapsone

4.4.5.1. Market size and forecast

4.4.6. Sulfasalazine

4.4.6.1. Market size and forecast

CHAPTER 5 BEHCET’S DISEASE MARKET, BY SYMPTOMS

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. EYES

5.2.1. Market size and forecast

5.3. BOWELS

5.3.1. Market size and forecast

5.4. SKIN AND MUCOSA

5.4.1. Market size and forecast

5.5. LUNGS

5.5.1. Market size and forecast

5.6. BRAIN

5.6.1. Market size and forecast

5.7. BONES

5.7.1. Market size and forecast

5.8. BLOOD VESSELS

5.8.1. Market size and forecast

5.9. HEART

5.9.1. Market size and forecast

CHAPTER 6 BEHCET’S DISEASE MARKET, BY GEOGRAPHY

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.2.4. North America Behcet’s Disease Market by Treatment Type
6.2.5. North America Behcet’s Disease Market by Symptoms

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Spain market size and forecast
6.3.3.5. Rest of Europe market size and forecast

6.3.4. Europe Behcet’s Disease Market by Treatment Type
6.3.5. Europe Behcet’s Disease Market by Symptoms

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. Rest of Asia-Pacific market size and forecast

6.4.4. Asia-Pacific Behcet’s Disease Market by Treatment Type
6.4.5. Asia-Pacific Behcet’s Disease Market by Symptoms

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Brazil market size and forecast
6.5.3.2. Turkey market size and forecast
6.5.3.3. Saudi Arabia market size and forecast
6.5.3.4. South Africa market size and forecast
6.5.3.5. Rest of LAMEA market size and forecast

6.5.4. LAMEA Behcet’s Disease Market by Treatment Type
6.5.5. LAMEA Behcet’s Disease Market by Symptoms

CHAPTER 7 COMPANY PROFILES

7.1. CREABILIS LTD.

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.2. CELL MEDICA LIMITED

7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments

7.3. ACTELION LTD

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.4. ABBOTT LABORATORIES

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. NOVARTIS AG

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. LES LABORATOIRES

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments

7.7. SERVIER SAS

7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments

7.8. ABBVIE INC.

7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments

7.9. CELGENE CORPORATION

7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments

7.10. F. Hoffmann-La Roche Ltd.

7.9.4. Operating business segments
7.9.5. Business performance
7.9.6. Key strategic moves and developments

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Online Only ~~$3,456~~ $3,041 Data Pack/Excel ~~$3,840~~ $3,379 Single User License ~~$5,370~~ $4,726 Five User License ~~$6,450~~ $5,676 Enterprise User License ~~$8,995~~ $7,916

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com